BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1845 related articles for article (PubMed ID: 11059782)

  • 1. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
    Boukerche H; Baril P; Tabone E; BĂ©rard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
    Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
    Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
    Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of Met-72 antigen expression: correlation with metastatic activity of B16 melanoma tumor cell variants.
    Kimura AK; Xiang JH
    J Natl Cancer Inst; 1986 Jun; 76(6):1247-54. PubMed ID: 3486997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice.
    Falcioni R; Kennel SJ; Giacomini P; Zupi G; Sacchi A
    Cancer Res; 1986 Nov; 46(11):5772-8. PubMed ID: 3756921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro properties of human melanoma cells metastatic in nude mice.
    Herlyn D; Iliopoulos D; Jensen PJ; Parmiter A; Baird J; Hotta H; Adachi K; Ross AH; Jambrosic J; Koprowski H
    Cancer Res; 1990 Apr; 50(8):2296-302. PubMed ID: 2156614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
    Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
    Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma.
    Mills L; Tellez C; Huang S; Baker C; McCarty M; Green L; Gudas JM; Feng X; Bar-Eli M
    Cancer Res; 2002 Sep; 62(17):5106-14. PubMed ID: 12208768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poorly metastatic tumor cell variants as primary targets of syngeneic antibody responses against murine melanoma.
    Parratto NP; Odebralski JM; Kimura AK
    Cancer Res; 1989 Jul; 49(14):3722-8. PubMed ID: 2736512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
    Huang S; Luca M; Gutman M; McConkey DJ; Langley KE; Lyman SD; Bar-Eli M
    Oncogene; 1996 Dec; 13(11):2339-47. PubMed ID: 8957075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-induced phosphorylation of a murine tumor surface protein (TSP-180) associated with metastatic phenotype.
    Sacchi A; Falcioni R; Piaggio G; Gianfelice MA; Perrotti N; Kennel SJ
    Cancer Res; 1989 May; 49(10):2615-20. PubMed ID: 2713845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-reactivity of murine anti-human high molecular weight-melanoma associated antigen monoclonal antibodies with guinea pig melanoma cells.
    Liao SK; Smith JW; Kwong PC; Natali PG; Kusama M; Hamby CV; Ferrone S
    Cancer Res; 1987 Sep; 47(18):4835-41. PubMed ID: 3476198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrin beta 3 cDNA transfection into a highly metastatic alpha v beta 3-negative human melanoma cell line inhibits invasion and experimental metastasis.
    Danen EH; van Kraats AA; Cornelissen IM; Ruiter DJ; van Muijen GN
    Biochem Biophys Res Commun; 1996 Sep; 226(1):75-81. PubMed ID: 8806594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells.
    Xie S; Price JE; Luca M; Jean D; Ronai Z; Bar-Eli M
    Oncogene; 1997 Oct; 15(17):2069-75. PubMed ID: 9366524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
    Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
    Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Establishment of a highly-metastatic model of human primary melanoma of the small intestine orthotopically transplanted in the small intestine of nude mice].
    Tuo CW; Zhang N; Liu QZ; Yang B; Wang MY
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):885-90. PubMed ID: 19173986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype.
    Bani MR; Rak J; Adachi D; Wiltshire R; Trent JM; Kerbel RS; Ben-David Y
    Cancer Res; 1996 Jul; 56(13):3075-86. PubMed ID: 8674065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions.
    Natali PG; Hamby CV; Felding-Habermann B; Liang B; Nicotra MR; Di Filippo F; Giannarelli D; Temponi M; Ferrone S
    Cancer Res; 1997 Apr; 57(8):1554-60. PubMed ID: 9108459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of a mouse monoclonal antibody, MoAb HMSA-1, against a melanosomal fraction of human malignant melanoma.
    Akutsu Y; Jimbow K
    Cancer Res; 1986 Jun; 46(6):2904-11. PubMed ID: 3516387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells.
    Burg MA; Grako KA; Stallcup WB
    J Cell Physiol; 1998 Nov; 177(2):299-312. PubMed ID: 9766527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression.
    Albelda SM; Mette SA; Elder DE; Stewart R; Damjanovich L; Herlyn M; Buck CA
    Cancer Res; 1990 Oct; 50(20):6757-64. PubMed ID: 2208139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 93.